Cytokinetics Shares are Jumping. Its Heart Drug Looks Better than Ever
1. Cytokinetics shares surged over 35% following positive trial data for aficamten. 2. FDA decision on aficamten approval is expected in late December 2023. 3. Trial results showed aficamten significantly outperformed metoprolol in key measures. 4. Analysts estimate aficamten sales could reach $2.3 billion by 2030. 5. Upcoming trial data on nonobstructive hypertrophic cardiomyopathy could further boost confidence.